Epsilogen

Executive Summary

Epsilogen is a UK-based biotechnology company pioneering the development of antibody therapeutics leveraging the unique properties of IgE, IgA, and IgG isotypes. Founded in 2018, the company exploits the differential effector functions of these antibody classes to optimize anti-cancer immune responses. By combining isotypes into single molecules, Epsilogen aims to broaden and enhance therapeutic efficacy. While still in early stages, the platform offers a novel approach to immunotherapy, potentially overcoming limitations of conventional IgG-only antibodies. The company is privately held and has not disclosed financial details or clinical stage candidates. Key challenges include translating preclinical promise into clinical benefit and navigating the manufacturing complexities of non-IgG antibodies. We assign a conviction score of 55, reflecting the innovative science balanced with early-stage risk.

Upcoming Catalysts (preview)

• H2 2026Lead candidate enters first-in-human clinical trial45% success
• TBDStrategic partnership or licensing deal for IgE-based platform30% success
• Q3 2026Publication of preclinical proof-of-concept data in a peer-reviewed journal70% success